Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-12

AUTHORS

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health

ABSTRACT

This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical ability). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance documents means that something is suggested or recommended but not required. First publication of the Draft Guidance by the Food and Drug Administration--February 2006. More... »

PAGES

79

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-7525-4-79

DOI

http://dx.doi.org/10.1186/1477-7525-4-79

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050813769

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17034633


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Industry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pain Measurement", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Satisfaction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Product Labeling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psychometrics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States Food and Drug Administration", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Montgomery County Department of Health and Human Services", 
          "id": "https://www.grid.ac/institutes/grid.414212.0", 
          "name": [
            "U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, 2085, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Montgomery County Department of Health and Human Services", 
          "id": "https://www.grid.ac/institutes/grid.414212.0", 
          "name": [
            "U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, 20852-1448, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Drive, 20850-430, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health", 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical ability). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance documents means that something is suggested or recommended but not required. First publication of the Draft Guidance by the Food and Drug Administration--February 2006.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1477-7525-4-79", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031326", 
        "issn": [
          "1477-7525"
        ], 
        "name": "Health and Quality of Life Outcomes", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance", 
    "pagination": "79", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f20e7b9f76632806fc808e60c7089143d866a7d8b4d41a8ccdfa40b804a67ace"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17034633"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101153626"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-7525-4-79"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050813769"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-7525-4-79", 
      "https://app.dimensions.ai/details/publication/pub.1050813769"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000516.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1477-7525-4-79"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7525-4-79'


 

This table displays all metadata directly associated to this object as RDF triples.

135 TRIPLES      20 PREDICATES      43 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-7525-4-79 schema:about N0e3f62f114494a5a90d7bb764143116a
2 N11d7412695074e1d9269f5da2724420b
3 N2620a97287be4916b2ebf8c2a8111f8e
4 N408ce9bad01c4538990cca9aa9fb2d28
5 N9ace99a834204199a768b10a3ca7373b
6 Nac9ff6beb0f647a58c520af56a982503
7 Nb6d5a9fcffdc4f27b88310b7f55e3a2e
8 Nb87f2e4cf0824c308901dfafe4e259b4
9 Ncaa1a57cc22f47c28e7b03e370afe44f
10 Nd5eebb33352845cc9cc2cbc08e168960
11 Ndcf0cdbb9a9e4e41acc8bd6987a6c7de
12 Nf4b91629b5aa4bdfb63473a5b957acc8
13 Nfaa48f6a439d43008656c356efdc3bed
14 Nfc0a0ee462b3466590a33569eea06f71
15 anzsrc-for:11
16 anzsrc-for:1117
17 schema:author N99581d87565e4048a88ba796567c7916
18 schema:datePublished 2006-12
19 schema:datePublishedReg 2006-12-01
20 schema:description This guidance describes how the FDA evaluates patient-reported outcome (PRO) instruments used as effectiveness endpoints in clinical trials. It also describes our current thinking on how sponsors can develop and use study results measured by PRO instruments to support claims in approved product labeling (see appendix point 1). It does not address the use of PRO instruments for purposes beyond evaluation of claims made about a drug or medical product in its labeling. By explicitly addressing the review issues identified in this guidance, sponsors can increase the efficiency of their endpoint discussions with the FDA during the product development process, streamline the FDA's review of PRO endpoint adequacy, and provide optimal information about the patient's perspective of treatment benefit at the time of product approval. A PRO is a measurement of any aspect of a patient's health status that comes directly from the patient (i.e., without the interpretation of the patient's responses by a physician or anyone else). In clinical trials, a PRO instrument can be used to measure the impact of an intervention on one or more aspects of patients' health status, hereafter referred to as PRO concepts, ranging from the purely symptomatic (response of a headache) to more complex concepts (e.g., ability to carry out activities of daily living), to extremely complex concepts such as quality of life, which is widely understood to be a multidomain concept with physical, psychological, and social components. Data generated by a PRO instrument can provide evidence of a treatment benefit from the patient perspective. For this data to be meaningful, however, there should be evidence that the PRO instrument effectively measures the particular concept that is studied. Generally, findings measured by PRO instruments may be used to support claims in approved product labeling if the claims are derived from adequate and well-controlled investigations that use PRO instruments that reliably and validly measure the specific concepts at issue. The glossary defines many of the terms used in this guidance. In particular, the term instrument refers to the actual questions or items contained in a questionnaire or interview schedule along with all the additional information and documentation that supports the use of these items in producing a PRO measure (e.g., interviewer training and instructions, scoring and interpretation manual). The term conceptual framework refers to how items are grouped according to subconcepts or domains (e.g., the item walking without help may be grouped with another item, walking with difficulty, within the domain of ambulation, and ambulation may be further grouped into the concept of physical ability). FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance documents means that something is suggested or recommended but not required. First publication of the Draft Guidance by the Food and Drug Administration--February 2006.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree true
24 schema:isPartOf Naca922317bbd405abe0158c4b5c643e4
25 Nca43e4838be44e168a112b555a30d8ad
26 sg:journal.1031326
27 schema:name Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
28 schema:pagination 79
29 schema:productId N018ddf0328a04bcdb37eb9b81853128b
30 N31a34c37f3bf447fb36fa11b3f60de97
31 N32333b4e972a46c5bb015cc9bafb7911
32 Na929e842121e4819a28cedcd62cb53b3
33 Nfb3e186aa9434f5fb0449f536dba1f26
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050813769
35 https://doi.org/10.1186/1477-7525-4-79
36 schema:sdDatePublished 2019-04-10T19:58
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N9c6a5b4c57414175adaa297e20295a6f
39 schema:url http://link.springer.com/10.1186%2F1477-7525-4-79
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N018ddf0328a04bcdb37eb9b81853128b schema:name readcube_id
44 schema:value f20e7b9f76632806fc808e60c7089143d866a7d8b4d41a8ccdfa40b804a67ace
45 rdf:type schema:PropertyValue
46 N07333cf328f64d688d4aca4df4a75244 schema:affiliation N41c5959e35fb49ff9b5de8f567ceba2a
47 schema:familyName U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health
48 rdf:type schema:Person
49 N0e3f62f114494a5a90d7bb764143116a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Treatment Outcome
51 rdf:type schema:DefinedTerm
52 N11d7412695074e1d9269f5da2724420b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Guidelines as Topic
54 rdf:type schema:DefinedTerm
55 N13ae132937f844dfa59474d069d9ac82 schema:affiliation https://www.grid.ac/institutes/grid.414212.0
56 schema:familyName U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research
57 rdf:type schema:Person
58 N2620a97287be4916b2ebf8c2a8111f8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Pain Measurement
60 rdf:type schema:DefinedTerm
61 N31a34c37f3bf447fb36fa11b3f60de97 schema:name dimensions_id
62 schema:value pub.1050813769
63 rdf:type schema:PropertyValue
64 N32333b4e972a46c5bb015cc9bafb7911 schema:name nlm_unique_id
65 schema:value 101153626
66 rdf:type schema:PropertyValue
67 N408ce9bad01c4538990cca9aa9fb2d28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Clinical Trials as Topic
69 rdf:type schema:DefinedTerm
70 N41c5959e35fb49ff9b5de8f567ceba2a schema:name U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Drive, 20850-430, Rockville, MD, USA
71 rdf:type schema:Organization
72 N99581d87565e4048a88ba796567c7916 rdf:first Nbafa0fadb0564c629d753d61dd15d9f4
73 rdf:rest Na2dcddce587c4fcd93e9f3296f86adf5
74 N9ace99a834204199a768b10a3ca7373b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Humans
76 rdf:type schema:DefinedTerm
77 N9c6a5b4c57414175adaa297e20295a6f schema:name Springer Nature - SN SciGraph project
78 rdf:type schema:Organization
79 Na2dcddce587c4fcd93e9f3296f86adf5 rdf:first N13ae132937f844dfa59474d069d9ac82
80 rdf:rest Ne7e331ec3d744152a3ac62b36442528c
81 Na929e842121e4819a28cedcd62cb53b3 schema:name pubmed_id
82 schema:value 17034633
83 rdf:type schema:PropertyValue
84 Nac9ff6beb0f647a58c520af56a982503 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Psychometrics
86 rdf:type schema:DefinedTerm
87 Naca922317bbd405abe0158c4b5c643e4 schema:issueNumber 1
88 rdf:type schema:PublicationIssue
89 Nb6d5a9fcffdc4f27b88310b7f55e3a2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Product Labeling
91 rdf:type schema:DefinedTerm
92 Nb87f2e4cf0824c308901dfafe4e259b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Quality of Life
94 rdf:type schema:DefinedTerm
95 Nbafa0fadb0564c629d753d61dd15d9f4 schema:affiliation https://www.grid.ac/institutes/grid.414212.0
96 schema:familyName U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research
97 rdf:type schema:Person
98 Nca43e4838be44e168a112b555a30d8ad schema:volumeNumber 4
99 rdf:type schema:PublicationVolume
100 Ncaa1a57cc22f47c28e7b03e370afe44f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Surveys and Questionnaires
102 rdf:type schema:DefinedTerm
103 Nd5eebb33352845cc9cc2cbc08e168960 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Patient Satisfaction
105 rdf:type schema:DefinedTerm
106 Ndcf0cdbb9a9e4e41acc8bd6987a6c7de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Drug Industry
108 rdf:type schema:DefinedTerm
109 Ne7e331ec3d744152a3ac62b36442528c rdf:first N07333cf328f64d688d4aca4df4a75244
110 rdf:rest rdf:nil
111 Nf4b91629b5aa4bdfb63473a5b957acc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name United States
113 rdf:type schema:DefinedTerm
114 Nfaa48f6a439d43008656c356efdc3bed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Data Interpretation, Statistical
116 rdf:type schema:DefinedTerm
117 Nfb3e186aa9434f5fb0449f536dba1f26 schema:name doi
118 schema:value 10.1186/1477-7525-4-79
119 rdf:type schema:PropertyValue
120 Nfc0a0ee462b3466590a33569eea06f71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name United States Food and Drug Administration
122 rdf:type schema:DefinedTerm
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
127 schema:name Public Health and Health Services
128 rdf:type schema:DefinedTerm
129 sg:journal.1031326 schema:issn 1477-7525
130 schema:name Health and Quality of Life Outcomes
131 rdf:type schema:Periodical
132 https://www.grid.ac/institutes/grid.414212.0 schema:alternateName Montgomery County Department of Health and Human Services
133 schema:name U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, 20852-1448, Rockville, MD, USA
134 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, 2085, Rockville, MD, USA
135 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...